Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review.

Abstract

The dramatic rise in the prevalence of obesity and diabetes is associated with increased morbidity, mortality, and public health care costs worldwide. The need for new, effective, and long-lasting drugs is urgent. Recent research has focused on the role of the inhibitors of sodium- glucose co-transporter 2 (SGLT-2). Clinical trials have shown that SGLT-2 inhibitors have glycemic efficacy and weight-lowering potential. Dual drug therapy is a recommended therapy for patients with new-onset type 2 diabetes who need significant glycemic control. Fixed-dose combination therapy represents a particularly attractive option as it may reduce pill burden and improve adherence. The combination of metformin and empagliflozin was approved by the US Food and Drug Administration in 2014 and represents a safe and effective means to combat glycemic control and weight gain. The purpose of this systematic review is to summarize the background of the SGLT-2 inhibitors, particularly empagliflozin, and focus on the safety and efficacy of the fixed-dose combination of empagliflozin and metformin.

• Authors: Rohit Kedia, Supriya Kulkarni, Meredith Ross, Vijay Shivaswamy
• Journal: Patient preference and adherence (Patient Prefer Adherence) Vol. 10 Pg. 1999-2006 ( 2016) ISSN: 1177-889X [Print] New Zealand
• PMID: 27757020 (Publication Type: Review, Journal Article)